MARKET

JANX

JANX

Janux Therapeutics, Inc.
NASDAQ
11.76
-0.63
-5.08%
Opening 13:45 11/12 EST
OPEN
11.86
PREV CLOSE
12.39
HIGH
11.99
LOW
11.50
VOLUME
526.26K
TURNOVER
--
52 WEEK HIGH
35.34
52 WEEK LOW
11.50
MARKET CAP
719.52M
P/E (TTM)
-7.3791
1D
5D
1M
3M
1Y
5Y
1D
Janux Therapeutics Cut to Peer Perform From Outperform by Wolfe Research
Dow Jones · 2h ago
Wolfe Research Downgrades Janux Therapeutics to Peer Perform
Benzinga · 3h ago
Wolfe downgrades Janux Therapeutics to Peer Perform on safety concerns
TipRanks · 5h ago
Analysts’ Top Healthcare Picks: enGene Holdings (ENGN), Janux Therapeutics Inc (JANX)
TipRanks · 6h ago
Stifel Nicolaus Sticks to Their Buy Rating for Janux Therapeutics Inc (JANX)
TipRanks · 2d ago
Piper Sandler Sticks to Their Buy Rating for Janux Therapeutics Inc (JANX)
TipRanks · 2d ago
UBS Reaffirms Their Hold Rating on Janux Therapeutics Inc (JANX)
TipRanks · 2d ago
Janux Therapeutics selloff after Phase 1 data ‘overdone,’ says William Blair
TipRanks · 2d ago
More
About JANX
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed three bispecific platforms: Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM). Its TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain. Its TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidates include JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr) designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and others.

Webull offers Janux Therapeutics Inc stock information, including NASDAQ: JANX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JANX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JANX stock methods without spending real money on the virtual paper trading platform.